Stock events for Moderna, Inc. (MRNA)
Over the past six months, Moderna's stock price has experienced fluctuations, with a 6-month return of +13.46% as of October 5, 2025. However, the share price as of October 3, 2025, was $28.48, representing a decline of 53.36% from $61.07 on October 3, 2024, and the 1-year return as of October 5, 2025, was -52.67%. In the first quarter of 2025, Moderna reported continued losses and declining sales of its COVID-19 vaccines, leading to plans for expanded cost efficiency and prioritization programs. Moderna's next earnings date is anticipated on November 6, 2025.
Demand Seasonality affecting Moderna, Inc.’s stock price
Demand for Moderna's COVID-19 vaccine is expected to be seasonal, with sales concentrated in the second half of the year, aligning with the fall and winter seasons as the vaccine transitions into a seasonal respiratory product. The company's first-quarter 2025 earnings also reflected the seasonality of its respiratory products. This seasonality is a key factor in Moderna's revenue projections, with a significant portion of its expected 2025 revenue anticipated in the latter half of the year.
Overview of Moderna, Inc.’s business
Moderna, Inc. is an American biotechnology company specializing in messenger RNA (mRNA) therapeutics and vaccines. The company's core business revolves around its mRNA therapeutics platform, which develops and produces human proteins, antibodies, and novel proteins to prevent, treat, and cure diseases. Moderna's major commercial products include the Moderna COVID-19 vaccine, marketed as Spikevax, and the respiratory syncytial virus (RSV) vaccine, marketed as mRESVIA. The company also has a robust pipeline of vaccine and therapeutic candidates in various stages of development, including vaccines for seasonal influenza, cytomegalovirus (CMV), and an individualized neoantigen therapy for oncology.
MRNA’s Geographic footprint
Moderna is headquartered in Cambridge, Massachusetts, U.S., with manufacturing units in Canada, the U.S., the UK, and Australia. The company has established subsidiaries in Japan, South Korea, and Australia, and plans to expand its commercial network across Asia. In September 2025, Moderna opened its Innovation and Technology Centre (MITC) in Oxfordshire, UK, which is the UK's first facility to manufacture mRNA vaccines onshore, with the capacity to produce up to 100 million mRNA vaccine doses annually, potentially increasing to 250 million during a pandemic.
MRNA Corporate Image Assessment
Moderna has generally enjoyed a stellar reputation, particularly due to its pioneering role in developing one of the first COVID-19 vaccines. However, the company has also faced challenges that could impact its brand, including patent disputes and scrutiny over executive stock sales. Moderna opened its Innovation and Technology Centre in the UK in September 2025, reaffirming its commitment to Britain and its strategic partnership with the UK government.
Ownership
Moderna's stock ownership is a mix of institutional, retail, and individual investors. Institutional investors hold a significant portion, with approximately 60.17%, 75.08%, or 75.33% of the company's stock, depending on the reporting source. Insiders own around 7.74%, and public companies and individual investors hold the remaining shares. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., Baillie Gifford & Co, Fmr Llc, State Street Corp, Geode Capital Management, Llc, and Morgan Stanley.
Ask Our Expert AI Analyst
Price Chart
$26.25